Acrivon Therapeutics’ Erick Gamelin sells 416 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Erick Gamelin, Acrivon Therapeutics' Chief Development Officer, reported selling 416 shares on November 17, 2026. The shares were sold automatically to meet mandatory tax withholding upon vesting of restricted stock units. He directly held 52,176 shares afterward. The reported $1.45 per-share price is a weighted average for 4,070 shares sold by a broker for a group of employees, including Gamelin; proceeds were allocated to employees pro rata. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 416 | $1.45 | $603.20 |
Footnotes (2)
- F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- F2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.
Key Figures
Key Terms
restricted stock units financial
mandatory tax withholding requirement financial
weighted average price financial
pro rata basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the $1.45 price in Erick Gamelin's ACRV Form 4 represent?
AI-generated analysis. How Rhea-AI works. Not financial advice.